Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. We have met the preestablished endpoint […]

(Note: Advaxis, Inc. withdrew its plan for a NASDAQ uplisting – a unit offering of stock and warrants – in an SEC filing dated June 27, 2022. The company did not intend to list the warrants on the NASDAQ. Advaxis filed an S-1 on May 12, 2022, for the public offering in connection with the […]

We are, through our, indirectly wholly owned HK SAR subsidiary, WANG & LEE CONTRACTING LIMITED, a construction prime contractor and a construction subcontractor engaging in the installation of Electrical & Mechanical Systems (“E&M”), which includes low voltage (220v/phase 1 or 380v/phase 3) electrical system, mechanical ventilation and air-conditioning system, fire service system, water supply and […]

(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTCQB Marketplace. Biostage, Inc. filed terms for its NASDAQ uplisting – a unit offering – in an S-1/A dated Oct. 27, 2022: 1.03 million units (1,034,000 units) at an assumed public offering price of $6.00 per unit. Each unit consists of one […]

(Note: Lamar Partnering Corp., a digital media and AdTech-focused blank check company or SPAC created by Lamar Advertising (LAMR), withdrew its IPO plans in an SEC filing dated June 21, 2022. Lamar Partnering Corp. filed its S-1 on April 6, 2021.) We intend to capitalize on the experience and skills of our management team and […]

Note: Ocean Capital Acquisition Corp. withdrew its SPAC IPO plans in a letter to the SEC on July 16, 2024. We will seek to acquire one or more businesses or assets that have a history of, or potential for, strong, stable cash flow generation, with predictable and recurring revenue streams. We will not be limited […]

(Note: Lionheart IV Corp., the fourth blank check company or SPAC backed by Lionheart Capital, withdrew its IPO plans in an SEC filing dated June 21, 2022. Lionheart IV had filed its S-1 on March 19, 2021, after filing confidential IPO paperwork on Feb. 16, 2021.) We may pursue an initial business combination target in […]

**NOTE: We, Hongli Group Inc. (“Hongli Cayman”), are an offshore holding company incorporated in the Cayman Islands. You are not investing in the PRC (People’s Republic of China) operating entities. Instead, we consolidate financial results of Hongli Shandong as our primary beneficiary through the Contractual Arrangements. Please see “Prospectus Summary — Corporate Information” for the summary of our […]

(Note: This is a micro-cap IPO: 1.5 million shares “of our common stock” offered by the company, which says it is using $4.00 – the low end of its $4.00-to-$5.00 range – as its assumed IPO price, “given market turmoil,” according to the S-1/A filing (amended prospectus) dated July 21, 2022. The prospectus cites “the […]

(Note: This is NOT an IPO. This is a NASDAQ uplisting from the OTC Pink Market. A reverse stock split – ratio to be determined – will be completed following the effective date, but before the closing of this public offering.) MusclePharm is a scientifically driven performance lifestyle company that develops, manufactures, markets and distributes […]